CRST – Clinical trials with over 25 years of experience

CRST is conducting a clinical study of a new drug for Alzheimer's Disease in Turku and Helsinki

Alzinova AB, a Swedish biopharma company announced that the Company has reached an important milestone where the last patient in the Phase 1b study with the vaccine candidate ALZ-101 against Alzheimer’s disease has been enrolled and received his first dose.

Read the original press release: alzinova-reaches-important-milestone-phase-1b-study-fully-recruited